Terms: = Leukemia AND BCL2, Bcl-2, 596, ENSG00000171791 AND Treatment
3243 results:
1.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract] [Full Text] [Related]
2. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in leukemia and Lymphoma Cells In Vitro.
Wilke N; Frias C; Berkessel A; Prokop A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731935
[TBL] [Abstract] [Full Text] [Related]
3. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant bcl-2.
Guo Y; Xue H; Hu N; Liu Y; Sun H; Yu D; Qin L; Shi G; Wang F; Xin L; Sun W; Zhang F; Song X; Li S; Wei Q; Guo Y; Li Y; Liu X; Chen S; Zhang T; Wu Y; Su D; Zhu Y; Xu A; Xu H; Yang S; Zheng Z; Liu J; Yang X; Yuan X; Hong Y; Sun X; Guo Y; Zhou C; Liu X; Wang L; Wang Z
J Med Chem; 2024 May; 67(10):7836-7858. PubMed ID: 38695063
[TBL] [Abstract] [Full Text] [Related]
5. Assessment of the
Nasr GM; Thawabieh OM; Talaat RM; Moawad M; El Hamshary MO
Front Biosci (Landmark Ed); 2024 Apr; 29(4):162. PubMed ID: 38682177
[TBL] [Abstract] [Full Text] [Related]
6. Improved Survival of Patients With Chronic Lymphocytic leukemia Between 1998-2022, Including the Era of Target Therapies With bcl2 and BTK Inhibitors.
Tadmor T; Melamed G; Alapi H; Gazit S; Patalon T; Rokach L
Anticancer Res; 2024 May; 44(5):2109-2115. PubMed ID: 38677726
[TBL] [Abstract] [Full Text] [Related]
7. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers.
Diepstraten ST; Yuan Y; La Marca JE; Young S; Chang C; Whelan L; Ross AM; Fischer KC; Pomilio G; Morris R; Georgiou A; Litalien V; Brown FC; Roberts AW; Strasser A; Wei AH; Kelly GL
Cancer Cell; 2024 May; 42(5):850-868.e9. PubMed ID: 38670091
[TBL] [Abstract] [Full Text] [Related]
8. [Research Progress of Targeted Therapy for Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma --Review].
Chen D; Wang MY; Tian C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
[TBL] [Abstract] [Full Text] [Related]
9. [Effect of Shikonin on Autophagy and Apoptosis of Human Promyelocytic leukemia Cells].
Chen Y; Xie XM; Zhang XL; Zhang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):416-421. PubMed ID: 38660845
[TBL] [Abstract] [Full Text] [Related]
10. Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia.
Adnan Awad S; Dufva O; Klievink J; Karjalainen E; Ianevski A; Pietarinen P; Kim D; Potdar S; Wolf M; Lotfi K; Aittokallio T; Wennerberg K; Porkka K; Mustjoki S
Cell Rep Med; 2024 May; 5(5):101521. PubMed ID: 38653245
[TBL] [Abstract] [Full Text] [Related]
11. Design, Synthesis, and Anti-Leukemic Evaluation of a Series of Dianilinopyrimidines by Regulating the Ras/Raf/MEK/ERK and STAT3/c-Myc Pathways.
Wang C; Wang B; Mou Y; Liu X; Chen Q; Pu W; Rao Q; Wang C; Song J; Huang Y; Yan L; Huang L; Li Y
Molecules; 2024 Apr; 29(7):. PubMed ID: 38611876
[TBL] [Abstract] [Full Text] [Related]
12. A novel α,β-unsaturated ketone inhibits leukemia cell growth as PARP1 inhibitor.
Zhao W; Mo M; Yu J; Cheng S; Long G; Luo Z; Liang W; Yan C; Luo H; Sun B
Med Oncol; 2024 Apr; 41(5):113. PubMed ID: 38602586
[TBL] [Abstract] [Full Text] [Related]
13. Targeting Myeloid leukemia-1 in Cancer Therapy: Advances and Directions.
Deng H; Han Y; Liu L; Zhang H; Liu D; Wen J; Huang M; Zhao L
J Med Chem; 2024 Apr; 67(8):5963-5998. PubMed ID: 38597264
[TBL] [Abstract] [Full Text] [Related]
14. Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia.
Wang K; Jiang M; Liu H; Meng C; Li M; Lu H
Bioorg Chem; 2024 Jun; 147():107319. PubMed ID: 38593529
[TBL] [Abstract] [Full Text] [Related]
15. Honokiol induces apoptosis and autophagy in dexamethasone-resistant T-acute lymphoblastic leukemia CEM-C1 cells.
Liu Y; Zhang S; Tan Y
Hematology; 2024 Dec; 29(1):2337307. PubMed ID: 38573223
[No Abstract] [Full Text] [Related]
16. [Safety and efficacy of 7-day administration of azacitidine and venetoclax combination therapy (7+7 therapy)].
Osada Y; Kanai-Sudo H; Mizuki T; Tanosaki S; Suzuki K
Rinsho Ketsueki; 2024; 65(3):135-141. PubMed ID: 38569855
[TBL] [Abstract] [Full Text] [Related]
17. [Study of a patient with Myelodysplastic/myeloproliferative neoplasm with co-morbid neutrophilia and a novel NCOR1::GLYR1 fusion gene].
Lei Y; Zhao X; Zhao H; Cheng Y; Wang S; Li J; Zhu Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):404-410. PubMed ID: 38565504
[TBL] [Abstract] [Full Text] [Related]
18. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A; Kantarjian H; Bataller A; Pemmaraju N; Borthakur G; Chien K; Alvarado Y; Bose P; Jabbour E; Yilmaz M; DiNardo C; Issa G; Montalban-Bravo G; Short N; Sasaki K; Bull-Linderman D; Daver N; Garcia-Manero G; Ravandi F; Kadia T
Lancet Haematol; 2024 Apr; 11(4):e287-e298. PubMed ID: 38548404
[TBL] [Abstract] [Full Text] [Related]
19. Evaluating population-level outcomes in Chronic Lymphocytic leukemia in the era of novel therapies using the SEER registry.
Muthiah C; Narra R; Atallah E; Juan W; Szabo A; Guru Murthy GS
Leuk Res; 2024 May; 140():107496. PubMed ID: 38547577
[TBL] [Abstract] [Full Text] [Related]
20. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
Hampel PJ; Swaminathan M; Rogers KA; Parry EM; Burger JA; Davids MS; Ding W; Ferrajoli A; Hyak JM; Jain N; Kenderian SS; Wang Y; Wierda WG; Woyach JA; Parikh SA; Thompson PA
Blood Adv; 2024 May; 8(10):2342-2350. PubMed ID: 38537065
[TBL] [Abstract] [Full Text] [Related]
[Next]
